Pulmonary drug administration provides a platform for the effective local treatment of various
respiratory diseases. Application of nano-sized active ingredients results in higher …

Pulmonary delivery has high bioavailability, a large surface area for absorption, and limited
drug degradation. Particle engineering is important to develop inhalable formulations to …

Meloxicam is an anti-inflammatory drug that could be interesting to deliver locally to the
lungs to treat inflammation occurring in cystic fibrosis or chronic obstructive pulmonary …

Coronavirus disease 2019 (COVID-19), caused by a new strain of coronavirus called severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide …

Particle engineering technologies have led to the commercialization of new inhaled
powders like PulmoSol TM or PulmoSphere TM. Such platforms are produced by spray …

Pulmonary inflammations such as chronic obstructive pulmonary disease and cystic fibrosis
are widespread and can be fatal, especially when they are characterized by abnormal …

A fatal hereditary condition, cystic fibrosis (CF) causes severe lung problems. Ibuprofen
(IBU), a non-steroidal anti-inflammatory drug, slows the progression of disease without …

With the increasing popularity and refinement of inhalation therapy, there has been a huge
demand for the design and development of fine-tuned inhalable drug particles capable of …

Inhalation is used for local therapy of the lungs and as an alternative route for systemic drug
delivery. Modern powder inhalation systems try to target the required site of …

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the
past decades. Researches are focusing on the formulation of carrier-free powders to obtain …